Bocunebart

博库奈拜单抗

Report date: 2025/11/10 15:47:20

Base Information

Drug NameBocunebart
Drug Alias NameAnti-PACAP-38-antibodyALD-1910LU-AG09222
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionPituitary adenylate cyclase-activating polypeptide type I receptor antagonists
TargetsPituitary adenylate cyclase-activating polypeptide type I receptor
Therapy Area/IndicationsMigraine DisordersRhinitis, Allergic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[15] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlder Biopharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesH. Lundbeck A/S
Inactive CompaniesN/A
Active IndicationsMigraine DisordersRhinitis, Allergic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A